New York, US, August 29 In recent years, exosome has played an increasingly obvious role in medical research and holds great potential for biomedical development. With many years of experience in the field of molecular and cellular biology research, great progress has been made for Creative Biolabs in terms of exosome purification service and exosome sequencing, thus providing fresh ideas and models for modern medical research and promising prospects for clinical application. As an important part of exosome research, purification and sequencing for exosome play an increasingly crucial role.
As we all know, exosomes are tiny 30-100nm vesicles secreted by most cell types in vivo and in vitro. They can be found in all body fluids, including plasma, saliva, and culture media for cell cultures. In some studies, exosome is available to be utilized for early clinical diagnosis and clinical risk or efficacy assessment of the tumor. Not only can it assist detect diseases such as prostate cancer, thereby potentially affecting disease progress, but it can also be used as a drug carrier to target tumors, treatment of diabetes, Parkinson's, and regeneration of muscles and tissues.
“Exosome can cross many barriers, such as brain barriers, making it ideal for the delivery of therapeutic molecules. Although it has been known for a long time, its application potential has increased tremendously in recent years. To better conduct exosome research, Creative Biolabs is equipped with the most advanced technologies and auxiliary tools to provide the most comprehensive support for exosome-related research and services. The platform plans to better discover clinical biomarkers and explore physiological functions from separation and characterization to cargo analysis and engineering”, said a senior scientist at Creative Biolabs.
Creative Biolabs has made an outstanding contribution to exosome purification services and created proven protocols to purify exosomes from plasma and other body fluids with decreased co-purification of non-exocrine proteins. To improve exosome concentration and its quality, several technologies have been developed for exosome purification, among which ultracentrifugation and microfiltration, size exclusion chromatography(SEC), and immunoaffinity capture are favored. Ultracentrifugation and microfiltration can reduce the co-purification of plenty of non-exosome proteins. SEC allows sample components to be separated based on the different rate of movement of the gel matrix through different size components. And the immunoaffinity capture method can selectively isolate and display the vesicles of interested surface markers. An experienced officer said proudly: "our skilled scientific team uses our advanced techniques to afford high purity, high yield, and efficient service as well as commendable after-sales service for exosome purification. To some extent, it can be a significant breakthrough in exosome research, which is probably to promote the process of biomarker research and improve progress in the field of transformational medicine”.
With the emergence of the next generation sequencing (NGS) technology, the study for exosome has been launched rapidly in a variety of diseases including cancer. At present, the team of experienced experts has made significant progress in exosome sequencing technology. The newly developed high-throughput sequencing technology can identify new transcripts and avoid background noise associated with fluorescence quantification. In other words, NGS exosome sequencing is rapidly becoming the first choice for transcriptional analysis. This technique has an accurate and sensitive quantitative measurement with no restrictions on any species.
The exosome services provided by the platform of Creative Biolabs will infiltrate the field of biotechnology. As a new vehicle, it is showing a promising future in the field of disease detection and treatment, which is of huge significance for the development of related clinical research.
About Creative Biolabs
As a leading bio-tech company, Creative Biolabs focuses on the development of new antibodies or analogues that provide the specificity and affinity required for research, diagnostic services or therapeutic applications. New antibodies with desired therapeutic properties can be designed and engineered by customizing the service to the specific requirements of the customer. For more information about our platform, please visit https://www.creative-biolabs.com/exosome.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email:Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biolabs.com/exosome
